Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides-Reference-Cited by-同舟云学术

Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides

Published:2017-09-06 Issue:44 Volume:8 Page:77567-77585
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Liu Jun¹,Bhadra Malini¹,Sinnakannu Joanna Rajeswary²,Yue Wan Lin¹³,Tan Cheryl Weiqi¹,Rigo Frank⁴,Ong S. Tiong²⁵⁶⁷,Roca Xavier¹

Affiliation:

1. School of Biological Sciences, Nanyang Technological University, Singapore

2. Cancer and Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore

3. CN Yang Scholars Programme, Nanyang Technological University, Singapore

4. Ionis Pharmaceuticals, Carlsbad, California, USA

5. Department of Haematology, Singapore General Hospital, Singapore

6. Department of Medical Oncology, National Cancer Centre Singapore, Singapore

7. Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protein isoform-centric therapeutics: expanding targets and increasing specificity;Nature Reviews Drug Discovery;2024-09-04

2. Overcoming cancer drug-resistance calls for novel strategies targeting abnormal alternative splicing;Pharmacology & Therapeutics;2024-09

3. Function of serine/arginine-rich splicing factors in hematopoiesis and hematopoietic malignancies;Cancer Cell International;2024-07-21

4. The Study of SRSF1 Regulates Abnormal Alternative Splicing of <i>BCL2L11</i> and the Role in Refractory Acute Myeloid Leukemia;Chemotherapy;2024-06-12

5. Development and validation of AI/ML derived splice-switching oligonucleotides;Molecular Systems Biology;2024-04-25